预约演示

Amgen, Merck KGaA add to budding constellation of ADC deals amid the modality's meteoric rise

2022-12-27

引进/卖出抗体药物偶联物ASCO会议

Amgen and Merck KGaA each announced new licensing pacts aimed at developing antibody-drug conjugates, joining one from Merck & Co. in the week leading up to Christmas.

Amgenool oMerck KGaAmas competing to develop game-changing antibody-drug conjugates continues to grow, with the water nMerck & Co.l after two more sizable licensing pacts.

Amgen and Merck KGaA each entered the holiday weekend with separate collaborations aimed at developing the burgeoning cancer-targeting modality, with the deals' combined value eclipsing $2 billion.

Amgenn MerMerck KGaA party started with an $830 million pact tapping Mersana Therapeutics, including $30 million in upcancercash in exchange for up to two targets. The deal, unveiled Thursday, lines up with Merck’s recent R&D ambitions, which include half of future product launches coming from external drug developers.

Amgen fMercked up the news by disclosing a deal of its own on Friday,Mersana Therapeutics$1.25 billion pact with LegoChem Biosciences for up to five ADC options. That deal provides further outside validationMerckegoChem’s ConjuAll ADC platform, which the company touts as delivering enhanced specificity for cancer targets coupled with drug payload technology. The deal with Amgen pushes the cumulative value of LegoChem’s 12 licensing deals past $5 billion.

Amgenwo deals added to the licensing money that flowed into the stockings of ADC-developing biotechs, after the ULegoChem Biosciences. inked a partneADCip last week with Kelun that could total $9 billion or moreLegoChemld, these thADC ADC deals eclipse $11 billion in potential biobucks, should any identifiecanceridates clear regulatory and clinical milestones.Amgen LegoChem

The announcements from Amgen and Merck KGaA also further validate antibody-drADCconjugates as a whole, which are arguably tMerck & Co.new therapeutic ticket in pharma.Kelun ADC

Their rise comes as theAmgenstry Merck KGaA to establish valiant competitors to the immuno-oncology behemoths and checkpoint inhibitors that have defined cancer therapies for the better part of the 2010s. ADC therapies merge a monoclonal antibody with a drug payload to reinvigorate the immune system's ability to fight cancer while treatment-bombing the disease directly.

The potential of ADCs is not a new revelation, but the therapies caught fire this summer after AstraZeneca and Daiichi Sankyo detailed stunning data of thcancerproved HER-2-directed breast cancer treatmentADC therapies the American Society of Clinical Oncology annual meeting.cancer

The drug-conjugate field is now continuing to bud, and beyond combinations with antibodies. FolAstraZenecan theDaiichi Sankyoerck & Co. tacked on a peptide-conjugate dHER-2-directed breast cancert licensing Enhertuon with PeptiDream Monday worth up to $2.1 billion. The number of targets on the table was not disclosed, but Merck will have the opportunity to exclusively pick up whatever candidates it elects to develop. The deal builds on an existing pact between Merck and PeptiDream that was first inked in April 2015.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构